Cobimetinib
Brand: Cotellic (global)
Anticancer
MEK inhibitor
Pharmacokinetics
| Half-life | 44 hours |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Given in cycles (21 days on, 7 days off). |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Rhabdomyolysis, CPK elevation, serous retinopathy, diarrhea
Contraindications:
Severe muscle disorders
Precautions:
Monitor CPK, ophthalmology evaluation for visual changes.